Typically after surgery, it is important to know what post-surgical options are available. Making the decision to enroll in a clinical trial is one of those options and maybe one of the most important decisions chondrosarcoma patients and their…
News
Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…
Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his…
Be Part of the First full Analysis of the Chondrosarcoma Patient Registry https://chondrosarcoma.iamrare.org It is not too late to sign up to participate in the Chondrosarcoma Patient Registry. The Chondrosarcoma Foundation has been preparing to…
Thank You!!!! To Everyone that participated in Chondrosarcoma Awareness Day. It is wonderful to see people from all over the globe come together to honor our CS survivors and those who lost their battle to this terrible bone cancer. And it is great…
Tomorrow, February 6 is Chondrsarcoma Awareness Day. Join the Fight Wear something Yellow. Take a picture (family, friends, work colleagues) and post it to #cswecare #chondrosarcoma #chondrosarcomafoundation Sign our Petition to support more…
This coming Tuesday, February 6 is Chondrsarcoma Awareness Day. Join the Fight Wear something Yellow. Take a picture (family, friends, work colleagues) and post it to #cswecare #chondrosarcoma #chondrosarcomafoundation Sign our Petition to…
Preclinical Characterization and Phase I Trial Results
of INBRX-109, A Third-Generation, Recombinant,
Humanized, Death Receptor 5 Agonist Antibody,
in Chondrosarcoma
Vivek Subbiah1, Sant P. Chawla2, Anthony P. Conley3, Breelyn A. Wilky4, Anthony…